Article info

Download PDFPDF

Original research
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study

Authors

  1. Correspondence to Dr Kazuhiro Kakimi, Department of Immunotherapeutics, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, Japan; kakimi{at}m.u-tokyo.ac.jp; Dr Kenzo Soejima, Clinical and Translational Research Center, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan; ksoejima{at}cpnet.med.keio.ac.jp; Dr Jun Nakajima, Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, Japan; NAKAJIMA-THO{at}h.u-tokyo.ac.jp
View Full Text

Citation

Kakimi K, Matsushita H, Masuzawa K, et al
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study

Publication history

  • Accepted August 14, 2020
  • First published September 18, 2020.
Online issue publication 
September 18, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.